Strontium increases vertebral bone volume in rats at a low dose that does not induce detectable mineralization defect.
Low doses of strontium and fluoride were shown to increase bone formation and trabecular bone density in rodents. To assess whether strontium or fluoride affect the quality of the mineral at doses known to increase bone density, we have determined the effects of low doses of strontium and fluoride on bone formation and bone mineral characteristics in rats. Adult rats were given strontium alone (0.20%), fluoride alone (1 mg/kg per day), or the combined treatment for 8 weeks. Strontium levels in serum and femur were similar in groups treated with strontium alone or in combination, being about 5% of calcium levels. Biochemical and neutron activation analyses in femur showed that calcium and magnesium contents did not differ in the four group of rats, suggesting that strontium was incorporated in the apatite lattice of the bone minerals in the strontium-treated rats. The mineralized bone volume was significantly increased by 17% in the strontium-treated group, by 20% in the fluoride-treated group, and by 19% in rats given with the combined treatment. This was associated with increased osteoid surface, osteoblast surface, and double tetracycline labeled surfaces in the strontium-treated and fluoride-treated groups, showing that the number of bone forming sites was increased. However, the mineral apposition rate, the osteoid thickness, and the mineralization lag time were similar in controls and treated groups, reflecting the lack of deleterious effects of low doses of strontium and fluoride on bone mineralization. The density fractionation analysis measured in the femur also showed that neither strontium, nor fluoride at the low doses used, significantly altered the mineralization profile. The results indicate that treatment with low doses of strontium or fluoride increase the number of bone forming sites and vertebral bone volume in rats, but does not have detectable adverse effects on the mineral profile, bone mineral chemistry or bone matrix mineralization.
Grynpas
M D
MD
Department of Pathology, University of Toronto, Canada.
Hamilton
E
E
Cheung
R
R
Tsouderos
Y
Y
Deloffre
P
P
Hott
M
M
Marie
P J
PJ
D000704:Analysis of Variance; D000818:Animals; D015519:Bone Density / Q000187:drug effects*; D001846:Bone Development / Q000187:drug effects*; D002113:Calcification, Physiologic / Q000187:drug effects; D002118:Calcium / Q000097:blood; D005269:Femur / Q000187:drug effects / Q000502:physiology; D005459:Fluorides / Q000494:pharmacology*; D008274:Magnesium / Q000097:blood; D008297:Male; D009501:Neutron Activation Analysis; D051381:Rats; D017207:Rats, Sprague-Dawley; D013054:Spectrophotometry, Atomic; D013131:Spine / Q000187:drug effects* / Q000502:physiology; D013324:Strontium / Q000097:blood / Q000494:pharmacology*
D008274:Magnesium; D005459:Fluorides; D002118:Calcium; D013324:Strontium